Islet Cell Transplantation

Principles of Regenerative Medicine

Volumn , Issue , 2008, Pages 794-811

  Emamaullee, Juliet A ^a   Shapiro, A M James ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863790321     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369410-2.50049-8     Document Type: Chapter

References (122)

1. Adams A.B. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 2002, 51:265-270.
2. Adams A.B. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J. Immunol. 2005, 174:542-550.
3. Ballinger .F., Lacy P.E. Transplantation of intact pancreatic islets in rats. Surgery 1972, 72:175-186.
4. Benhamou P.Y. Immunomodulation with CTLA4-Ig in islet transplantation. Transplantation 2002, 73:S40-S42.
5. Benhamou P.Y. Human islet transplantation network for the treatment of type I diabetes: first data from the Swiss-French GRAGIL consortium (1999-2000). Groupe de Recherch. Diabetologia 2001, 44:859-864.
6. Bennet W. Incompatibility between human blood and isolated islets of langerhans: a finding with implications for clinical intraportal islet transplantation?. Diabetes 1999, 48:1907-1914.
7. Bhargava R. Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes 2004, 53:1311-1317.
8. Biarnes M. Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 2002, 51:66-72.
9. Bonner-Weir S., Weir G.C. New sources of pancreatic beta-cells. Nat. Biotechnol. 2005, 23:857-861.
10. Bosi E. Autoantibody response to islet transplantation in type 1 diabetes. Diabetes 2001, 50:2464-2471.
11. Bougneres P.F. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990, 39:1264-1272.
12. Brendel M.H.B., Schulz A., Bretzel R. International Islet Transplant Registry Report 2001, 1. University of Giessen, Germany.
13. Cardona K. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat. Med. 2006, 12:304-306.
14. Carlsson P.O. Markedly decreased oxygen tension in transplanted rat pancreatic islets irrespective of the implantation site. Diabetes 2001, 50:489-495.
15. Carlsson P.O. Low revascularization of experimentally transplanted human pancreatic islets. J. Clin. Endocrinol.Metab. 2002, 87:5418-5423.
16. Casey J.J. Portal venous pressure changes after sequential clinical islet transplantation. Transplantation 2002, 74:913-915.
17. Cattan P. Destruction of conditional insulinoma cell lines in NOD mice: a role for autoimmunity. Diabetologia 2003, 46:504-510.
18. Contreras J.L. Brain death significantly reduces isolated pancreatic islet yields and functionality in vitro and in vivo after transplantation in rats. Diabetes 2003, 52:2935-2942.
19. Contreras J.L. Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammat. Diabetes 2004, 53:2804-2814.
20. Cottet S. SOCS-1 protein prevents Janus Kinase/STAT-dependent inhibition of beta cell insulin gene transcription and secretion in response to interferon-gamma. J. Biol. Chem. 2001, 276:25862-25870.
21. Cottet S. cFLIP protein prevents tumor necrosis factor-alpha-mediated induction of caspase-8-dependent apoptosis in insulin-secreting betaTc-Tet cells. Diabetes 2002, 51:1805-1814.
22. Davalli A.M. A selective decrease in the beta cell mass of human islets transplanted into diabetic nude mice. Transplantation 1995, 59:817-820.
23. DCCT Research Group Diabetes Care 1990, 13:427-433.
24. DCCT Research Group The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993, 329:977-986.
25. DCCT Research Group Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995, 18:1415.
26. Desai N.M. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity?. Transplantation 2003, 76:1623-1625.
27. Dionne K.E. Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans. Diabetes 1993, 42:12-21.
28. Djamali A. Outcomes in kidney transplantation. Semin. Nephrol. 2003, 23:306-316.
29. Dupraz P. Lentivirus-mediated Bcl-2 expression in betaTC-tet cells improves resistance to hypoxia and cytokine-induced apoptosis while preserving in vitro and in vivo control of insulin secretion. Gene Ther. 1999, 6:1160-1169.
30. Dupraz P. Dominant negative MyD88 proteins inhibit interleukin-1beta/interferon-gamma-mediated induction of nuclear factor kappa B-dependent nitrite production and apop. J. Biol. Chem. 2000, 275:37672-37678.
31. Eisenbarth G.S. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res. 1985, 2:271-276.
32. Elliott R.B. Partial preservation of pancreatic beta-cell function in children with diabetes. Lancet 1981, 2:631-632.
33. Elliott R.B. No evidence of infection with porcine endogenous retrovirus in recipients of encapsulated porcine islet xenografts. Cell Transplant. 2000, 9:895-901.
34. Emamaullee J.A. XIAP Overexpression in islet beta-cells enhances engraftment and minimizes hypoxiareperfusion injury. Am. J. Transplant. 2005, 5:1297-1305.
35. Emamaullee J.A. XIAP Overexpression in human islets prevents early post-transplant apoptosis and reduces the islet mass needed to treat diabetes. Diabetes 2005, 54:2541-2548.
36. Fishman J.A., Patience C. Xenotransplantation: infectious risk revisited. Am. J. Transplant 2004, 4:1383-1390.
37. Giuliani M. Central necrosis in isolated hypoxic human pancreatic islets: evidence for postisolation ischemia. Cell Transplant 2005, 14:67-76.
38. Goss J.A. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet. Transplantation 2002, 74:1761-1766.
39. Goss J.A. Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolation center. Transplantation 2004, 77:462-466.
40. Grey S.T. A20 inhibits cytokine-induced apoptosis and nuclear factor kappaB-dependent gene activation in islets. J. Exp.Med. 1999, 190:1135-1146.
41. Grey S.T. Genetic engineering of a suboptimal islet graft with A20 preserves beta cell mass and function. J. Immunol 2003, 170:6250-6256.
42. Gross C.R. Quality of life after pancreas transplantation: a review. Clin. Transplant. 1998, 12:351-361.
43. Groth C.G. Transplantation of porcine fetal pancreas to diabetic patients. Lancet 1994, 344:1402-1404.
44. Gruessner A.C., Sutherland D.E. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas. Clin. Transplant. 2005, 19:433-455.
45. Gruessner R.W. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996, 61:261-273.
46. Gruessner R.W. Transplant options for patients undergoing total pancreatectomy for chronic pancreatitis. J. Am. Coll. Surg. 2004, 198:559-567. discussion 568-569.
47. Hering B.J. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am. J. Transplant 2004, 4:390-401.
48. Hering B.J. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005, 293:830-835.
49. Hering B.J. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat. Med. 2006, 12:301-303.
50. Hering B.R.C. Islet transplantation for patients with type 1 diabetes: results, research priorities, and reasons for optimism. Graft 1999, 2:12.
51. Herold K.C. A single course of anti-CD3 monoclonal antibody hOKT31(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years aft. Diabetes 2005, 54:1763-1769.
52. Hyder A. Effect of the immunosuppressive regime of Edmonton protocol on the long-term in vitro insulin secretion from islets of two different species and age categ. Toxicol. In Vitro 2005, 19:541-546.
53. International Islet Transplant Registry 2005a.
54. Jaeger C. Islet autoantibodies as potential markers for disease recurrence in clinical islet transplantation. Exp. Clin. Endocrinol. Diabetes. 2000, 108:328-333.
55. Jindal R.M. Post-transplant diabetes mellitus: the role of immunosuppression. Drug Saf. 1997, 16:242-257.
56. Kaplan B. Effect of sirolimus withdrawal in patients with deteriorating renal function. Am. J. Transplant 2004, 4:1709-1712.
57. Kawai T. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. 2000, 6:114.
58. Keen H. The Diabetes Control and Complications Trial (DCCT). Health Trends 1994, 26:41-43.
59. Kelly D. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 1967, 61:827-837.
60. Kemp C.B. Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats. Diabetologia 1973, 9:486-491.
61. Kempf M.C. Logistics and transplant coordination activity in the GRAGIL Swiss-French multicenter network of islet transplantation. Transplantation 2005, 79:1200-1205.
62. Kendall D.M. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing type I diabetes and autonomi. Diabetes 1997, 46:249-257.
63. Kenyon N.S. Long-term survival and function of intrahepatic islet allografts in Rhesus monkeys treated with humanized anti-CD154. Proc. Natl Acad. Sci. USA 1999, 96:8132-8137.
64. King H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431.
65. Kirk A.D. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. USA 1997, 94:8789-8794.
66. Kirk A.D. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 1999, 5:686-693.
67. Klein D. Delivery of Bcl-XL or its BH4 domain by protein transduction inhibits apoptosis in human islets. Biochem. Biophys. Res. Commun. 2004, 323:473-478.
68. Lacy P.E., Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967, 16:35-39.
69. Lakey J.R. Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation 1996, 61:1047-1053.
70. Larsen J.L. Pancreas transplantation: indications and consequences. Endocr. Rev 2004, 25:919-946.
71. Lenschow J. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp.Med. 1995, 181:1145-1155.
72. Levisetti M.G. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J. Immunol. 1997, 159:5187-5191.
73. Matsumoto S. Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet 2005, 365:1642-1644.
74. Merrill J.P. Successful transplantation of kidney from a human cadaver. JAMA 1963, 185:347-353.
75. Moberg L. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002, 360:2039-2045.
76. Molinari M. Sirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two cases. Am. J. Transplant. 2005, 5:2799-2804.
77. Murray J.E. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N. Engl. J.Med. 1963, 268:1315-1323.
78. Narang A.S. Vascular endothelial growth factor gene delivery for revascularization in transplanted human islets. Pharm. Res 2004, 21:15-25.
79. Nathan D.M. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N. Engl. J. Med. 2003, 348:2294-2303.
80. Nathan D.M. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 2005, 353:2643-2653.
81. National Diabetes Data Group (US) Diabetes in America. National Institutes of Health 1995, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
82. Newell K.A. Comparison of pancreas transplantation with portal venous and enteric exocrine drainage to the standard technique utilizing bladder drainage of exocrine secre. Transplantation 1996, 62:1353-1356.
83. Otonkoski T. Stem cells in the treatment of diabetes. Ann.Med. 2005, 37:513-520.
84. Owen R.J. Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects. Radiology 2003, 229:165-170.
85. Owen S. Pediatric pumps: barriers and breakthroughs. Diabetes Educ. 2006, 32:29S-38S.
86. Ozmen L. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inh. Diabetes 2002, 51:1779-1784.
87. Pearson T. Islet cell autoimmunity and transplantation tolerance: two distinct mechanisms?. Ann. NY Acad. Sci. 2003, 1005:148-156.
88. Phelps C.J. Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003, 299:411-414.
89. Plesner A. The X-linked inhibitor of apoptosis protein enhances survival of murine islet allografts. Diabetes 2005, 54:2533-2540.
90. Rabinovitch A., Suarez-Pinzon .L. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem. Pharmacol 1998, 55:1139-1149.
91. Reckard C.R. Physiological and immunological consequences of transplanting isolated pancreatic islets. Surgery 1973, 74:91-99.
92. Ricordi C. Automated islet isolation from human pancreas. Diabetes 1989, 38(Suppl 1):140-142.
93. Ricordi C. Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation 1992, 53:407-414.
94. Rood P.P., Cooper D.K. Islet xenotransplantation: are we really ready for clinical trials?. Am. J. Transplant. 2006, 6:1269-1274.
95. Rood P.P. Pig-to-nonhuman primate islet xenotransplantation: a review of current problems. Cell Transplant 2006, 15:89-104.
96. Rossini A.A. Islet cell transplantation tolerance. Transplantation 2001, 72:S43-S46.
97. Ryan E.A. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002, 51:2148-2157.
98. Ryan E.A. Risks and side effects of islet transplantation. Curr. Diabetes Rep. 2004, 4:304-309.
99. Ryan E.A. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004, 53:955-962.
100. Ryan E.A. Five-year follow-up after clinical islet transplantation. Diabetes 2005, 54:2060-2069.
101. Scharp .W. Insulin independence after islet transplantation into type I diabetic patient. Diabetes 1990, 39:515-518.
102. Secchi A. Effect of pancreas transplantation on life expectancy, kidney function and quality of life in uraemic type 1 (insulin-dependent) diabetic patients. Diabetologia 1991, 34(Suppl 1):S141-S144.
103. Senior P.A. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am. J. Transplant. 2005, 5:2318-2323.
104. Shapiro A.M. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoidfree immunosuppressive regimen. N. Engl. J. Med. 2000, 343:230-238.
105. Shapiro A.M. Edmonton's islet success has indeed been replicated elsewhere. Lancet 2003, 362:1242.
106. Shapiro A.M. The portal immunosuppressive storm: relevance to islet transplantation?. Ther. Drug Monit. 2005, 27:35-37.
107. Shapiro A.M. Strategic opportunities in clinical islet transplantation. Transplantation 2005, 79:1304-1307.
108. Silverstein J. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N. Engl. J. Med. 1988, 319:599-604.
109. Statistical Data Reported by the US Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network 2005.
110. Sutherland D.E. Transplantation of dispersed pancreatic islet tissue in humans: autografts and allografts. Diabetes 1980, 29(Suppl 1):31-44.
111. Sutherland D.E. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann. Surg. 2001, 233:463-501.
112. Tsujimura T. Influence of pancreas preservation on human islet isolation outcomes: impact of the two-layer method. Transplantation 2004, 78:96-100.
113. Tzakis A.G. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet 1990, 336:402-405.
114. Valdes-Gonzalez R.A. Xenotransplantation of porcine neonatal islets of Langerhans and sertoli cells: a 4- year study. Eur. J. Endocrinol. 2005, 153:419-427.
115. Villiger P. Prevention of bleeding after islet transplantation: lessons learned from a multivariate analysis of 132 cases at a single institution. Am. J. Transplant. 2005, 5:2992-2998.
116. Vincenti F. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 2005, 353:770-781.
117. Walsh T.J. Portal hypertension, hepatic infarction, and liver failure complicating pancreatic islet autotransplantation. Surgery 1982, 91:485-487.
118. Williams P. Notes on diabetes treated with extract and by grafts of sheep's pancreas. BMJ 1894, 2:1303-1304.
119. World Health Organization Diabetes: The Cost of Diabetes 2002, (No. 236). Vol. Fact Sheet. http://www.who.int/mediacentre/factsheets/f36/en/print.html.
120. Zalzman M. Reversal of hyperglycemia in mice by using human expandable insulin-producing cells differentiated from fetal liver progenitor cells. Proc. Natl Acad. Sci. USA. 2003, 100:7253-7258.
121. Zalzman M. Differentiation of human liver-derived, insulin-producing cells toward the beta-cell phenotype. Diabetes 2005, 54:2568-2575.
122. International Islet Transplant Registry 2005a.